The problem of low adherence to antiresorptive therapy with bisphosphonates: solutions

Медицинский совет

O. V. Yakushevskaya¹ 

[1] Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology;

关键词: osteoporosis;    antiresorptive therapy;    bisphosphonates;    alendronate;    adverse events;   

DOI  :  10.21518/2079-701X-2021-21-1-175-180

来源: DOAJ

【 摘 要 】

Over the past several decades, there has been a global aging of the population around the world. The demographic situation in the Russian Federation is no exception, being a natural result of an increase in the life expectancy of the population. In clinical practice, geriatric diseases have been identified and are widely studied, which deserve priority attention due to a sharp decline in the quality of life of elderly patients. Osteoporosis is called a “silent epidemic” among elderly and senile patients. This disease is associated with a high risk of low-traumatic fractures of various localization. The imperfect rehabilitation program after complex fractures and its insufficient funding are forcing clinicians to focus on more cost-effective solutions to this problem  – the  prevention and treatment of  osteoporosis. Osteomodifying agents are widely used by physicians of  various specialties. Bisphosphonates effectively reduce the risk of low-traumatic fractures against the background of an increase in bone mineral density. The  level of  effectiveness of  bisphosphonates depends on the  patient’s adherence to antiresorptive therapy and the degree of compensation for vitamin D and serum calcium. Low adherence to osteoporosis therapy is based on the need for long-term use of bisphosphonates and a different spectrum of adverse events. In the article, using alendronate as an example, the problem of low adherence to antiresorptive therapy will be considered and ways to solve it are presented.

【 授权许可】

Unknown